User profiles for Charles N. Bernstein

Charles N Bernstein

Distinguished Professor of Medicine, University of Manitoba
Verified email at umanitoba.ca
Cited by 73904

Diversity of the human intestinal microbial flora

PB Eckburg, EM Bik, CN Bernstein, E Purdom… - science, 2005 - science.org
The human endogenous intestinal microflora is an essential “organ” in providing nourishment,
regulating epithelial development, and instructing innate immunity; yet, surprisingly, basic …

[HTML][HTML] Infliximab maintenance therapy for fistulizing Crohn's disease

BE Sands, FH Anderson, CN Bernstein… - … England Journal of …, 2004 - Mass Medical Soc
Background Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective
maintenance therapy for patients with Crohn's disease without fistulas. It is not known …

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress …

…, T Ahmad, IDR Arnott, CN Bernstein… - Canadian Journal of …, 2005 - hindawi.com
The discovery of a series of genetic and serological markers associated with disease
susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an …

Cancer risk in patients with inflammatory bowel disease: a population‐based study

CN Bernstein, JF Blanchard, E Kliewer, A Wajda - Cancer, 2001 - Wiley Online Library
BACKGROUND The objective of the current study was to determine the incidence of cancer
among persons with inflammatory bowel disease (IBD) and to compare these incidence …

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

CN Bernstein, JF Blanchard… - Official journal of the …, 2001 - journals.lww.com
OBJECTIVE: The aim of this study was to determine the prevalence of the major extraintestinal
manifestations of inflammatory bowel disease (IBD) and their relation to disease …

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

…, MA Kamm, M Boivin, CN Bernstein… - Gastroenterology, 2005 - Elsevier
Background & Aims: To investigate the efficacy and safety of certolizumab pegol (a
polyethylene-glycolated Fab′ fragment of anti–tumor necrosis factor, CDP870) in Crohn’s disease. …

The epidemiology of inflammatory bowel disease in Canada: a population-based study

CN Bernstein, A Wajda, LW Svenson… - Official journal of the …, 2006 - journals.lww.com
BACKGROUND Previously, we have demonstrated a high incidence and prevalence of Crohn's
disease (CD) and ulcerative colitis (UC) in the Canadian province of Manitoba. However…

Environmental triggers in IBD: a review of progress and evidence

AN Ananthakrishnan, CN Bernstein… - Nature reviews …, 2018 - nature.com
n-3 polyunsaturated fatty acid (PUFA) intake has been inversely associated with risk of ulcerative
colitis, whereas dietary n… induced colitis in mice, dietary n-3 PUFAs reduced the clinical …

The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study

CN Bernstein, JF Blanchard… - Thrombosis and …, 2001 - thieme-connect.com
Background: There is an impression mostly from specialty clinics that patients with inflammatory
bowel disease (IBD) have an increased risk of venous thromboembolic disorders. Our …

Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study

CN Bernstein, JF Blanchard… - American journal of …, 1999 - academic.oup.com
The aim of this study was to assess the accuracy and utility of administrative health data in
identifying persons with inflammatory bowel disease on a population basis and to determine …